iRhythm Technologies (IRTC) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
27 May, 2026Opening remarks and agenda
The meeting was called to order by the CEO, with board members and executive leadership present virtually, enhancing stockholder access and reducing costs.
The agenda included an overview of meeting matters, presentation of proposals, voting, and a Q&A session.
Board and executive committee updates
Nine directors were nominated for election to serve one-year terms expiring at the 2027 annual meeting.
Shareholder proposals
Five proposals were presented: election of directors, approval of the 2026 Equity Incentive Plan, amendment of the certificate of incorporation, ratification of KPMG LLP as auditors, and an advisory vote on executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from iRhythm Technologies
- Q1 growth, AI innovation, and expanded patient access drive strong outlook and margin gains.IRTC
Bank of America Global Healthcare Conference 202619 May 2026 - Q1 2026 revenue up 26% to $199.4M, with margin gains and raised full-year guidance.IRTC
Q1 20261 May 2026 - Annual meeting to vote on directors, equity plan, auditor, and executive pay amid strong growth and ESG focus.IRTC
Proxy filing17 Apr 2026 - Key votes include director elections, equity plan approval, and auditor ratification.IRTC
Proxy filing17 Apr 2026 - AI-driven cardiac monitoring, record 2025 revenue, and global expansion fuel strong growth.IRTC
44th Annual J.P. Morgan Healthcare Conference12 Apr 2026 - Proxy covers director elections, new equity plan, auditor change, and strong pay-for-performance.IRTC
Proxy filing6 Apr 2026 - Record 2025 growth, first positive net income, and strong 2026 outlook with margin expansion.IRTC
Q4 202519 Feb 2026 - Long-term monitoring leads market growth, with new products and partnerships fueling 2025 momentum.IRTC
2024 Truist Securities MedTech Conference3 Feb 2026 - Q2 revenue up 19.3% to $148M; guidance raised amid strong demand and ongoing regulatory risks.IRTC
Q2 20242 Feb 2026